<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01119131</url>
  </required_header>
  <id_info>
    <org_study_id>B7051-W</org_study_id>
    <nct_id>NCT01119131</nct_id>
  </id_info>
  <brief_title>Effects of Vitamin D in Parkinson's Disease (PD)</brief_title>
  <official_title>The Effects of Vitamin D on Balance in Persons With PD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A trial to measure the effects of vitamin D (versus a placebo) on balance, gait, falls,
      strength, and cognition in persons with Parkinson's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a randomized, double-blinded, placebo controlled intervention trial to
      measure the effects of vitamin D at (10,000IU/day) versus placebo on balance and falls in
      Parkinson's disease. The investigators will measure static, dynamic, and ambulatory balance,
      as well as strength, falls, and cognition before and after 16 weeks of therapy. Dynamic
      posturography will be used to measure static and ambulatory balance, a device called
      iMOBILITY will measure a timed up and go, and strength will be measured with the Biodex
      machine checking knee flexion and extension. Multiple quality of life and cognitive tests
      will also be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Static Balance as Recorded Using Dynamic Posturography With the Sensory Organization Test (SOT 1-3)</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Sensory organization test (SOT) is a form of posturography. which is designed to assess quantitatively an individual`s ability to use visual, proprioceptive and vestibular cues to maintain postural stability in stance. The SOT measures sway during 6 scenarios. In scenarios 1-3 the base is stable and eyes are open, then closed, and then the visual surround moves. SOT 1-3 is an average measurement of equilibrium - the average center of gravity sway for each condition. It generates a score of 0 (fall) up to 100 for each scenario and an overall composite score. Change score is measurement at 16 weeks minus measurement at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Ambulatory Balance Measured by Instrumented Timed up and go (iTUG) Turn Duration</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>This is a test that measures ambulatory balance and mobility. The instrumented timed up and go (iTUG) is an average time (seconds) of three trials that involve the participant arising from a chair, walking 25 feet turning around, walking back to the chair, and sitting down. The turn duration is the average time to turn at the end of the 25 foot walk. Longer duration of time (seconds) indicates more rigidity, a proxy measure for &quot;ON&quot; time in Parkinson's disease. Change score is measurement at 16 weeks minus measurement at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Strength as Recorded by Measuring Knee Flexion Using Biodex (Total Work)</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Defined as the total muscular force output for the repetition with the greatest amount of work. The equation for work is: W = F x D. Change score is measurement at 16 weeks minus measurement at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Dynamic Balance as Recorded Using Dynamic Posturography With the Sensory Organization Test (SOT 4-6)</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Sensory organization test (SOT) is a form of posturography. which is designed to assess quantitatively an individual`s ability to use visual, proprioceptive and vestibular cues to maintain postural stability in stance. The SOT measures sway during 6 scenarios. In 4-6 the base moves and the subject has eyes open, then closed, then the visual surround moves. SOT 4-6 is an average measurement of equilibrium - the average center of gravity sway for each condition. It generates a score of 0 (fall) up to 100 for each scenario and an overall composite score. Change score is measurement at 16 weeks minus measurement at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Strength as Recorded by Measuring Knee Extension Using Biodex (Total Work)</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Defined as the total muscular force output for the repetition with the greatest amount of work. The equation for work is: W = F x D. Change score is measurement at 16 weeks minus measurement at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cognition (Trail Making Test B-A)</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>The Trail Making Test (TMT) consists of two parts (A &amp; B) in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy. The test provides information about visual search speed, scanning, speed of processing, and executive functioning. Part A measures processing speed and part B measures executive functioning. The TMT is time to complete each part of the test in seconds. Higher scores indicate greater impairment. Subtracting part A from part B is theorized to reduce the influence of the working memory and visuospatial demands and, therefore, provides a relatively pure indicator of executive function. Change score is measurement (Part B - Part A) at 16 weeks minus measurement (Part B - Part A) at baseline, negative scores indicate a improvement in executive functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life as Recorded Using Quality of Life Scales (PDQ39)</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>The PDQ39 is a 39 item patient completed survey targeting well-being and functioning in PD. This scale address 8 dimensions (mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort). The PDQ39 dimension scores are on a scale of 0 (&quot;Never&quot;) to 4 (&quot;Always/Cannot Do&quot;). Scale scores are summed and range from 0 to 100 with 100 being the maximum level of problems. For a single index figure to characterize the impact of Parkinson's disease upon PD patients (PDSI), all 39 items of the PDQ39 can be summed. The PDQ39 and the use of a PDSI have shown adequate reliability and convergent validity. Change score is measurement at 16 weeks minus baseline measurement, negative scores indicate an improvement in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Parkinsonism as Measured by the UPDRS</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>This is the motor subsection of the UPDRS and is a commonly used tool to rate the symptoms of Parkinson's disease. This scale rates from 0 (normal) to 4 (Can barely perform the task) several motor areas including speech, facial expression, tremor, rigidity, hand movements, agility, posture, and gait. A sum score represents motor function with higher values on this scale represent a more severe stage of the disease. Change is measurement at 16 weeks minus baseline measurement, negative scores indicate an improvement in Parkinson's motor symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Accidental Falls</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will be on high dose vitamin D3 (10,000 IU daily) and 1000 mg of calcium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Will be on placebo and 1000mg of calcium.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 at 10,000 IU a day</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcium</intervention_name>
    <description>1000mg calcium daily</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Parkinson's disease;

          -  ability to ambulate 50 feet;

          -  ability to cooperate with balance testing;

          -  vitamin D level less than 40ng/ml;

          -  balance problems;

          -  ability to walk 50 feet without the help of another person

        Exclusion Criteria:

          -  MMSE &lt; 25;

          -  another neurological or orthopedic deficit that in the examiner's opinion would affect
             testing;

          -  history of renal stones or hypercalcemia;

          -  unwillingness to not be on other vitamin D supplementation during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amie Hiller, MD BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Portland Health Care System, Portland, OR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Portland Health Care System, Portland, OR</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>May 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2010</study_first_posted>
  <results_first_submitted>November 17, 2015</results_first_submitted>
  <results_first_submitted_qc>February 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 7, 2016</results_first_posted>
  <last_update_submitted>February 8, 2016</last_update_submitted>
  <last_update_submitted_qc>February 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Parkinson disease</keyword>
  <keyword>accidental falls</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from two large treatment centers in the Pacific Northwest and from the community during the time period 2011 – 2014.</recruitment_details>
      <pre_assignment_details>Excluded (n=33) Not meeting criteria (n=32) (16 have vitamin D levels that were too high, 4 hx of renal stones, 3 with a history of tuberculosis, and 9 other) Lost to follow-up (n=1)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D (Open Label)</title>
          <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
        </group>
        <group group_id="P2">
          <title>Vitamin D</title>
          <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Will be on placebo and 1000mg of calcium.
calcium: 1000mg calcium daily
Placebo: A placebo pill with similar appearance to the vitamin D will be given to those in the placebo arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D (Open Label)</title>
          <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
        </group>
        <group group_id="B2">
          <title>Vitamin D</title>
          <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Will be on placebo and 1000mg of calcium.
calcium: 1000mg calcium daily
Placebo: A placebo pill with similar appearance to the vitamin D will be given to those in the placebo arm</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.1" spread="8.0"/>
                    <measurement group_id="B2" value="64.5" spread="8.0"/>
                    <measurement group_id="B3" value="68.8" spread="8.1"/>
                    <measurement group_id="B4" value="67.2" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hoehn &amp; Yahr</title>
          <description>This is an objective staging scale for rating the clinical functioning of Parkinson’s disease patients, combining functional deficits (disability) and objective signs (impairment). This staging scale is commonly used in both research settings and clinical practice. The Hoehn &amp; Yahr is an ordinal scale ranging from 0 (no signs of disease) to 5 (wheelchair bound/bedridden). The modified version of the scale includes increments of 0.5. The HY has shown good inter-rater reliability and, although it is used worldwide, the clinimetric validity has not been established.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.35" spread="0.34"/>
                    <measurement group_id="B2" value="2.48" spread="0.46"/>
                    <measurement group_id="B3" value="2.46" spread="0.47"/>
                    <measurement group_id="B4" value="2.45" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>UPDRS</title>
          <description>This is the motor subsection of the UPDRS and is a commonly used tool to rate the symptoms of Parkinson‘s disease. Each item is rated from 0 (normal) to 4 (Can barely perform the task) several motor areas including speech, facial expression, tremor, rigidity, hand movements, agility, posture, and gait. Total score ranges from 0 to 108 with higher values on this scale represent a more severe stage of the disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.20" spread="11.06"/>
                    <measurement group_id="B2" value="22.36" spread="8.56"/>
                    <measurement group_id="B3" value="25.3" spread="11.5"/>
                    <measurement group_id="B4" value="23.93" spread="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Vitamin D</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.7" spread="3.86"/>
                    <measurement group_id="B2" value="30.21" spread="5.32"/>
                    <measurement group_id="B3" value="29.43" spread="6.46"/>
                    <measurement group_id="B4" value="27.59" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MoCA</title>
          <description>The MoCA is a short cognitive screening test designed to assist health care professionals for the detection of mild cognitive impairment. The MoCA assesses cognitive function across a variety of domains, such as visuospatial /executive functioning, naming (animals), memory, attention, language, abstraction, delayed recall, and orientation. The MoCA is scored on a 0 to 30 scale, with lower numbers indicating more cognitive impairment. A point is added to the MoCA if the subject's education high school or less (12 years or less education).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.67" spread="1.94"/>
                    <measurement group_id="B2" value="24.07" spread="2.91"/>
                    <measurement group_id="B3" value="24.86" spread="3.00"/>
                    <measurement group_id="B4" value="24.78" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Falls Self-Report</title>
          <units>Falls</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.86" spread="14.18"/>
                    <measurement group_id="B2" value="3.79" spread="14.85"/>
                    <measurement group_id="B3" value="3.05" spread="7.26"/>
                    <measurement group_id="B4" value="3.75" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Static Balance as Recorded Using Dynamic Posturography With the Sensory Organization Test (SOT 1-3)</title>
        <description>Sensory organization test (SOT) is a form of posturography. which is designed to assess quantitatively an individual`s ability to use visual, proprioceptive and vestibular cues to maintain postural stability in stance. The SOT measures sway during 6 scenarios. In scenarios 1-3 the base is stable and eyes are open, then closed, and then the visual surround moves. SOT 1-3 is an average measurement of equilibrium - the average center of gravity sway for each condition. It generates a score of 0 (fall) up to 100 for each scenario and an overall composite score. Change score is measurement at 16 weeks minus measurement at baseline.</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>Missing data N=2, test not performed due to participant fatigue.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D (Open Label)</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Will be on placebo and 1000mg of calcium.
calcium: 1000mg calcium daily
Placebo: A placebo pill with similar appearance to the vitamin D will be given to those in the placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Static Balance as Recorded Using Dynamic Posturography With the Sensory Organization Test (SOT 1-3)</title>
          <description>Sensory organization test (SOT) is a form of posturography. which is designed to assess quantitatively an individual`s ability to use visual, proprioceptive and vestibular cues to maintain postural stability in stance. The SOT measures sway during 6 scenarios. In scenarios 1-3 the base is stable and eyes are open, then closed, and then the visual surround moves. SOT 1-3 is an average measurement of equilibrium - the average center of gravity sway for each condition. It generates a score of 0 (fall) up to 100 for each scenario and an overall composite score. Change score is measurement at 16 weeks minus measurement at baseline.</description>
          <population>Missing data N=2, test not performed due to participant fatigue.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.25" spread="2.93"/>
                    <measurement group_id="O2" value="2.05" spread="8.85"/>
                    <measurement group_id="O3" value="1.78" spread="21.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.699</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Ambulatory Balance Measured by Instrumented Timed up and go (iTUG) Turn Duration</title>
        <description>This is a test that measures ambulatory balance and mobility. The instrumented timed up and go (iTUG) is an average time (seconds) of three trials that involve the participant arising from a chair, walking 25 feet turning around, walking back to the chair, and sitting down. The turn duration is the average time to turn at the end of the 25 foot walk. Longer duration of time (seconds) indicates more rigidity, a proxy measure for &quot;ON&quot; time in Parkinson’s disease. Change score is measurement at 16 weeks minus measurement at baseline.</description>
        <time_frame>Baseline and 16 weeks</time_frame>
        <population>Missing data N=14, test not performed due to either participant fatigue (N = 2) or mechanical/computer issues (N = 12).</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D (Open Label)</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Will be on placebo and 1000mg of calcium.
calcium: 1000mg calcium daily
Placebo: A placebo pill with similar appearance to the vitamin D will be given to those in the placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ambulatory Balance Measured by Instrumented Timed up and go (iTUG) Turn Duration</title>
          <description>This is a test that measures ambulatory balance and mobility. The instrumented timed up and go (iTUG) is an average time (seconds) of three trials that involve the participant arising from a chair, walking 25 feet turning around, walking back to the chair, and sitting down. The turn duration is the average time to turn at the end of the 25 foot walk. Longer duration of time (seconds) indicates more rigidity, a proxy measure for &quot;ON&quot; time in Parkinson’s disease. Change score is measurement at 16 weeks minus measurement at baseline.</description>
          <population>Missing data N=14, test not performed due to either participant fatigue (N = 2) or mechanical/computer issues (N = 12).</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.25"/>
                    <measurement group_id="O2" value="0.09" spread="0.54"/>
                    <measurement group_id="O3" value="-0.07" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.308</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Strength as Recorded by Measuring Knee Flexion Using Biodex (Total Work)</title>
        <description>Defined as the total muscular force output for the repetition with the greatest amount of work. The equation for work is: W = F x D. Change score is measurement at 16 weeks minus measurement at baseline.</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>Missing data N=4, test not performed due to participant fatigue (N = 2), mechanical/computer issues (N = 1), illness of operator (N = 1).</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D (Open Label)</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Will be on placebo and 1000mg of calcium.
calcium: 1000mg calcium daily
Placebo: A placebo pill with similar appearance to the vitamin D will be given to those in the placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Strength as Recorded by Measuring Knee Flexion Using Biodex (Total Work)</title>
          <description>Defined as the total muscular force output for the repetition with the greatest amount of work. The equation for work is: W = F x D. Change score is measurement at 16 weeks minus measurement at baseline.</description>
          <population>Missing data N=4, test not performed due to participant fatigue (N = 2), mechanical/computer issues (N = 1), illness of operator (N = 1).</population>
          <units>foot pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.07" spread="117.40"/>
                    <measurement group_id="O2" value="6.89" spread="176.40"/>
                    <measurement group_id="O3" value="35.19" spread="80.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.419</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cognition (Trail Making Test B-A)</title>
        <description>The Trail Making Test (TMT) consists of two parts (A &amp; B) in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy. The test provides information about visual search speed, scanning, speed of processing, and executive functioning. Part A measures processing speed and part B measures executive functioning. The TMT is time to complete each part of the test in seconds. Higher scores indicate greater impairment. Subtracting part A from part B is theorized to reduce the influence of the working memory and visuospatial demands and, therefore, provides a relatively pure indicator of executive function. Change score is measurement (Part B - Part A) at 16 weeks minus measurement (Part B - Part A) at baseline, negative scores indicate a improvement in executive functioning.</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>Missing data (N = 8) due to scheduling difficulties (N = 3), neuropsychological administration errors (N = 2), patient discontinuing (N = 1), maximum time allowance met and discontinued test (N = 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D (Open Label)</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Will be on placebo and 1000mg of calcium.
calcium: 1000mg calcium daily
Placebo: A placebo pill with similar appearance to the vitamin D will be given to those in the placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cognition (Trail Making Test B-A)</title>
          <description>The Trail Making Test (TMT) consists of two parts (A &amp; B) in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy. The test provides information about visual search speed, scanning, speed of processing, and executive functioning. Part A measures processing speed and part B measures executive functioning. The TMT is time to complete each part of the test in seconds. Higher scores indicate greater impairment. Subtracting part A from part B is theorized to reduce the influence of the working memory and visuospatial demands and, therefore, provides a relatively pure indicator of executive function. Change score is measurement (Part B - Part A) at 16 weeks minus measurement (Part B - Part A) at baseline, negative scores indicate a improvement in executive functioning.</description>
          <population>Missing data (N = 8) due to scheduling difficulties (N = 3), neuropsychological administration errors (N = 2), patient discontinuing (N = 1), maximum time allowance met and discontinued test (N = 2).</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" spread="30.89"/>
                    <measurement group_id="O2" value="12.13" spread="49.83"/>
                    <measurement group_id="O3" value="-17.33" spread="74.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.253</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life as Recorded Using Quality of Life Scales (PDQ39)</title>
        <description>The PDQ39 is a 39 item patient completed survey targeting well-being and functioning in PD. This scale address 8 dimensions (mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort). The PDQ39 dimension scores are on a scale of 0 (&quot;Never&quot;) to 4 (&quot;Always/Cannot Do&quot;). Scale scores are summed and range from 0 to 100 with 100 being the maximum level of problems. For a single index figure to characterize the impact of Parkinson’s disease upon PD patients (PDSI), all 39 items of the PDQ39 can be summed. The PDQ39 and the use of a PDSI have shown adequate reliability and convergent validity. Change score is measurement at 16 weeks minus baseline measurement, negative scores indicate an improvement in quality of life.</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>Missing data (N = 3), patient forgot form and did not return mailed form (N = 3).</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D (Open Label)</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Will be on placebo and 1000mg of calcium.
calcium: 1000mg calcium daily
Placebo: A placebo pill with similar appearance to the vitamin D will be given to those in the placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life as Recorded Using Quality of Life Scales (PDQ39)</title>
          <description>The PDQ39 is a 39 item patient completed survey targeting well-being and functioning in PD. This scale address 8 dimensions (mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort). The PDQ39 dimension scores are on a scale of 0 (&quot;Never&quot;) to 4 (&quot;Always/Cannot Do&quot;). Scale scores are summed and range from 0 to 100 with 100 being the maximum level of problems. For a single index figure to characterize the impact of Parkinson’s disease upon PD patients (PDSI), all 39 items of the PDQ39 can be summed. The PDQ39 and the use of a PDSI have shown adequate reliability and convergent validity. Change score is measurement at 16 weeks minus baseline measurement, negative scores indicate an improvement in quality of life.</description>
          <population>Missing data (N = 3), patient forgot form and did not return mailed form (N = 3).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.96"/>
                    <measurement group_id="O2" value="-0.02" spread="0.47"/>
                    <measurement group_id="O3" value="-0.14" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.793</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Dynamic Balance as Recorded Using Dynamic Posturography With the Sensory Organization Test (SOT 4-6)</title>
        <description>Sensory organization test (SOT) is a form of posturography. which is designed to assess quantitatively an individual`s ability to use visual, proprioceptive and vestibular cues to maintain postural stability in stance. The SOT measures sway during 6 scenarios. In 4-6 the base moves and the subject has eyes open, then closed, then the visual surround moves. SOT 4-6 is an average measurement of equilibrium - the average center of gravity sway for each condition. It generates a score of 0 (fall) up to 100 for each scenario and an overall composite score. Change score is measurement at 16 weeks minus measurement at baseline.</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>Missing data N=3, test not performed due to participant fatigue (N = 2) or computer/mechanical error (N = 1).</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D (Open Label)</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Will be on placebo and 1000mg of calcium.
calcium: 1000mg calcium daily
Placebo: A placebo pill with similar appearance to the vitamin D will be given to those in the placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Dynamic Balance as Recorded Using Dynamic Posturography With the Sensory Organization Test (SOT 4-6)</title>
          <description>Sensory organization test (SOT) is a form of posturography. which is designed to assess quantitatively an individual`s ability to use visual, proprioceptive and vestibular cues to maintain postural stability in stance. The SOT measures sway during 6 scenarios. In 4-6 the base moves and the subject has eyes open, then closed, then the visual surround moves. SOT 4-6 is an average measurement of equilibrium - the average center of gravity sway for each condition. It generates a score of 0 (fall) up to 100 for each scenario and an overall composite score. Change score is measurement at 16 weeks minus measurement at baseline.</description>
          <population>Missing data N=3, test not performed due to participant fatigue (N = 2) or computer/mechanical error (N = 1).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="11.91"/>
                    <measurement group_id="O2" value="2.272" spread="12.63"/>
                    <measurement group_id="O3" value="-1.89" spread="14.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Strength as Recorded by Measuring Knee Extension Using Biodex (Total Work)</title>
        <description>Defined as the total muscular force output for the repetition with the greatest amount of work. The equation for work is: W = F x D. Change score is measurement at 16 weeks minus measurement at baseline.</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>Missing data N=4, test not performed due to participant fatigue (N = 2), mechanical/computer issues (N = 1), illness of operator (N = 1).</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D (Open Label)</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Will be on placebo and 1000mg of calcium.
calcium: 1000mg calcium daily
Placebo: A placebo pill with similar appearance to the vitamin D will be given to those in the placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Strength as Recorded by Measuring Knee Extension Using Biodex (Total Work)</title>
          <description>Defined as the total muscular force output for the repetition with the greatest amount of work. The equation for work is: W = F x D. Change score is measurement at 16 weeks minus measurement at baseline.</description>
          <population>Missing data N=4, test not performed due to participant fatigue (N = 2), mechanical/computer issues (N = 1), illness of operator (N = 1).</population>
          <units>foot pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.11" spread="66.65"/>
                    <measurement group_id="O2" value="23.33" spread="83.16"/>
                    <measurement group_id="O3" value="17.49" spread="32.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.949</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Parkinsonism as Measured by the UPDRS</title>
        <description>This is the motor subsection of the UPDRS and is a commonly used tool to rate the symptoms of Parkinson‘s disease. This scale rates from 0 (normal) to 4 (Can barely perform the task) several motor areas including speech, facial expression, tremor, rigidity, hand movements, agility, posture, and gait. A sum score represents motor function with higher values on this scale represent a more severe stage of the disease. Change is measurement at 16 weeks minus baseline measurement, negative scores indicate an improvement in Parkinson's motor symptoms.</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <population>Missing data (N = 2), invalid sum due to missing rating (N = 1), not completed due to scheduling conflicts (N = 1).</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D (Open Label)</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D</title>
            <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Will be on placebo and 1000mg of calcium.
calcium: 1000mg calcium daily
Placebo: A placebo pill with similar appearance to the vitamin D will be given to those in the placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Parkinsonism as Measured by the UPDRS</title>
          <description>This is the motor subsection of the UPDRS and is a commonly used tool to rate the symptoms of Parkinson‘s disease. This scale rates from 0 (normal) to 4 (Can barely perform the task) several motor areas including speech, facial expression, tremor, rigidity, hand movements, agility, posture, and gait. A sum score represents motor function with higher values on this scale represent a more severe stage of the disease. Change is measurement at 16 weeks minus baseline measurement, negative scores indicate an improvement in Parkinson's motor symptoms.</description>
          <population>Missing data (N = 2), invalid sum due to missing rating (N = 1), not completed due to scheduling conflicts (N = 1).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="8.33"/>
                    <measurement group_id="O2" value="0.48" spread="5.60"/>
                    <measurement group_id="O3" value="-0.18" spread="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.957</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D (Open Label)</title>
          <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
        </group>
        <group group_id="E2">
          <title>Vitamin D</title>
          <description>Will be on high dose vitamin D (10,000 IU daily) and 1000 mg of calcium
Vitamin D: Vitamin D at 10,000 IU a day
calcium: 1000mg calcium daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Will be on placebo and 1000mg of calcium.
calcium: 1000mg calcium daily
Placebo: A placebo pill with similar appearance to the vitamin D will be given to those in the placebo arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Illness</sub_title>
                <description>Non-Specified Illness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amie Hiller, MD</name_or_title>
      <organization>VA Portland Health Care System</organization>
      <phone>503.721.1091</phone>
      <email>peterami@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

